Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2026 05:31 ET | Source: Research and Markets

Allergy Diagnostics and Therapeutics Market Research Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Allergy Diagnostics and Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" report has been added to ...
January 22, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
January 20, 2026 10:15 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for...
January 16, 2026 05:00 ET | Source: Nouscom Srl

Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an off-the-shelf cancer immunotherapy designed to induce...
January 09, 2026 07:00 ET | Source: Immunocore Holdings plc

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US...
January 07, 2026 09:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences
January 05, 2026 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Announces Key Leadership Appointments

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
December 16, 2025 12:18 ET | Source: Equity Insider

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic...
December 16, 2025 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Announces Initiation of Dosing in a Phase 1 Trial of EVOLVE104 in Patients with Solid Tumors

EVOLVE104, a First-in-Class CD2 Costimulatory Trispecific T Cell Engager, is First Molecule from EVOLVE Platform to Enter the Clinic Trial Initiation Marks EvolveImmune’s Transition to Clinical-Stage...
December 12, 2025 10:31 ET | Source: Equity Insider

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal...